

IPSEN IN BRIEF 2022

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.



DIANA
Living with post-stroke spasticity
Sintra, Portugal

OUR STRATEGY

Focus. Together.
For patients & society

**Maximize
our brands**



**Drive
efficiencies**



**Strengthen
pipeline**



**Focus on
culture**



CSR STRATEGY 2024 AMBITIONS

Employees

- Best place to work certification in **>75%** of countries
- Gender balance in global leadership team
- Fill **65%** of leadership roles via internal promotion

Environment

- **21%** reduction of greenhouse gas emissions
- **24%** reduction of water consumption
- **20%** reduction of process waste

Communities

- More than **1/3** of employees supporting healthcare and environment communities
- Continue support for IFPMA Access Accelerated initiative

IPSEN KEY FIGURES

€2.9bn

TOTAL SALES (2021)

5,700+

COLLEAGUES

100+

COUNTRIES WHERE
IPSEN MEDICINES ARE
MARKETED

25+

MEDICINES

The Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs:

Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

THERAPEUTIC AREAS

ONCOLOGY

More than **35 years of research** in **Oncology** focusing on cancers with high unmet needs



RARE DISEASE

Teams of **global experts and researchers** developing life-changing treatments for **Rare Diseases**


PALOVAROTENE

NEUROSCIENCE

More than **25 years** of **Neuroscience** expertise and innovation



TOTAL SALES AND GROWTH*



GEOGRAPHIC BREAKDOWN

Total sales by region: 2021

32%


NORTH AMERICA

31%

EU5

37%

REST OF THE WORLD



FINANCIAL OUTLOOK* 2020 TO 2024



Total sales CAGR to 2024 between +4% & +6%



Commitment to invest in R&D, supported by SG&A efficiencies



€3.5bn cumulative remaining firepower for pipeline expansion



Craig Marks, Vice President, Investor Relations
+44 (0) 7584 349 193



Adrien Dupin de Saint-Cyr, Investor Relations Manager
+33 (0) 6 64 26 17 49

investor.relations@ipsen.com
ipsen.com/investors



*All growth rates are at constant exchange rates.